EMA Reviewing Two MAb Combinations For COVID-19

Products Being Assessed Under Special Procedure For EU Member States

The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.

European Union flag with covid-19 coronavirus in background
More products for use in COVID-19 are being assessed in Europe • Source: Shutterstock

The European Medicines Agency is carrying out a review of two monoclonal antibody combinations with potential in treating COVID-19, under a special procedure that assists the EU member states in making medicinal products available in emergency situations before they have been formally approved.

The two combinations in question are casirivimab/imdevimab and bamlanivimab/etesevimab. The first is being co-developed as REGN-COV2 by 

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography